Emily Singer

A View from Emily Singer

A New Vaccine Against Multiple Sclerosis

Initial human tests show the vaccine appears safe and triggers beneficial changes in the brain.

  • August 14, 2007

An experimental DNA vaccine against multiple sclerosis (MS) appears safe in early human tests and shows signs of effectiveness, according to a paper published Monday in the online version of the Archives of Neurology.

In MS, the immune system attacks the fatty coating, known as myelin, protecting nerve cells in the brain and spinal cord, eventually destroying nerve cells’ ability to communicate. The cause of the disease is unknown.

In the study, headed by Amit Bar-Or of the Montreal Neurological Institute in Canada, patients were given a vaccine made up of one of the protein components of myelin. The idea is that the vaccine will damp the body’s tendency to attack myelin.

While larger studies are needed to determine if the vaccine will truly help MS patients, initial results were promising. The vaccine appears safe and showed early signs of a beneficial effect on the immune system: the number of immune cells in the spinal fluid that attack myelin was reduced in a small subset of patients who underwent lumbar puncture. A larger study of the vaccine is now under way.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Basic.
  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning magazine and daily delivery of The Download, our newsletter of what’s important in technology and innovation.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.